NVO · 高风险高回报 · High Risk Reward

诺和诺德（Novo Nordisk）曾是全球市值最高的欧洲企业，市值一度突破约6000亿美元。2025年，股价从约$82高位跌至约$36，跌幅超过55%——GLP-1竞争格局恶化、CagriSema三期数据不及预期、Ozempic与Wegovy在中国、巴西、加拿大专利到期、管理层大换血，一切利空在同一年密集爆发。

Novo Nordisk was once the European company with the highest market capitalization in the world, with its market cap once exceeding approximately $600 billion. In 2025, the stock price fell from a high of approximately $82 to approximately $36, a decline of over 55%—deterioration of the GLP-1 competitive landscape, CagriSema Phase 3 data falling short of expectations, patent expirations for Ozempic and Wegovy in China, Brazil, and Canada, and a major management shake-up, all negative catalysts erupted intensively within the same year.

市场把一年的坏消息全部打入了股价。

The market has priced a year's worth of bad news into the stock price.

但让我们分清楚这次下跌改变了什么，以及没有改变什么。

But let us distinguish between what this decline has changed and what it has not.

改变了的：CagriSema的市场预期，三期数据减重22.7%未达25%目标，令下一代管线可信度受损。Ozempic与Wegovy在部分市场的专利保护期，2026年起陆续在加拿大、巴西、中国面临仿制药竞争。2026年全年营收与利润的增长预期，管理层已明确引导为下行年。

What has changed: Market expectations for CagriSema, with Phase 3 data showing 22.7% weight loss failing to meet the 25% target, damaging the credibility of the next-generation pipeline. The patent protection periods for Ozempic and Wegovy in certain markets, facing generic competition in Canada, Brazil, and China starting from 2026. Growth expectations for full-year 2026 revenue and profit, which management has explicitly guided as a down year.

没有改变的：诺和诺德是全球GLP-1市场的原创者与最大商业化平台这个事实。口服Wegovy已于2026年1月正式在美国上市，售价约$149/月，开辟了注射剂无法覆盖的庞大新患者群体。下一代候选药物amycretin在二期数据中展示了高达22%的减重效果，已于2026年一季度正式启动三期临床，若数据成立，其单分子设计在疗效与生产成本上均优于CagriSema。Wegovy在MASH（代谢相关脂肪性肝炎）新适应症的获批，开辟了与肥胖症并行的全新收入来源。当前市盈率约11倍，不足医疗保健板块平均18倍的三分之二，股息收益率约4.67%，提供了价值底部支撑。

What has not changed: The fact that Novo Nordisk is the creator and largest commercialization platform of the global GLP-1 market. Oral Wegovy was officially launched in the U.S. in January 2026, priced at approximately $149/month, opening up a vast new patient population that injectables could not cover. The next-generation candidate drug amycretin demonstrated weight loss effects as high as 22% in Phase 2 data and officially started Phase 3 clinical trials in the first quarter of 2026; if the data holds, its single-molecule design is superior to CagriSema in both efficacy and production cost. The approval of Wegovy for the new indication of MASH (metabolic dysfunction-associated steatohepatitis) has opened up a completely new revenue stream parallel to obesity. The current P/E ratio is approximately 11 times, less than two-thirds of the healthcare sector average of 18 times, and the dividend yield of approximately 4.67% provides a value floor support.

市场将一年的集中利空定价为结构性终局。但GLP-1的全球渗透率依然极低，口服剂型的普及将大幅扩大可及人群，amycretin的三期进程是市场尚未充分定价的隐性期权。今天约$36的折价，是在用一个周期性低谷的价格，出售全球最具规模的肥胖症治疗平台。

The market has priced a year of concentrated negatives as a structural endgame. However, the global penetration rate of GLP-1 remains extremely low, the popularization of oral dosage forms will significantly expand the accessible population, and the Phase 3 progress of amycretin is an implicit option that the market has not yet fully priced. Today's discount at approximately $36 is selling the world's most scaled obesity treatment platform at the price of a cyclical trough.

下半部分，我们拆解三重错位逻辑、具体建仓价位与三个阶段止盈目标，以及触发重新评估的具体条件。

In the second half, we deconstruct the triple misalignment logic, specific entry price levels, and three-stage take-profit targets, as well as the specific conditions that trigger a re-evaluation.

为什么现在是关键交易窗口

Why this is a critical trading window now

第一重错位：口服Wegovy开辟全新市场，市场只定价了注射剂的竞争压力，完全忽略了口服剂型的增量价值

Triple Misalignment 1: Oral Wegovy opens a brand new market; the market has only priced in the competitive pressure of injectables, completely ignoring the incremental value of the oral dosage form.

注射剂Wegovy的竞争对手是Eli Lilly的Zepbound，这场竞争市场已经充分定价。但口服Wegovy以约$149/月的自费价格进入市场，其目标用户是那些对注射剂有心理抵触、或此前从未接受治疗的庞大潜在患者群。全球肥胖症患者超过10亿，目前GLP-1药物的渗透率仍处于极低水平。口服剂型不是注射剂的替代，而是市场的扩张。这部分增量，在当前股价中几乎没有体现。

The competitor for injectable Wegovy is Eli Lilly’s Zepbound, a competition the market has already fully priced in. However, oral Wegovy entered the market at an out-of-pocket price of approximately $149/month, targeting a vast potential patient group that has psychological resistance to injectables or has never received treatment before. There are over 1 billion obesity patients globally, and the penetration rate of GLP-1 drugs remains at an extremely low level. The oral dosage form is not a replacement for injectables, but an expansion of the market. This incremental portion is hardly reflected in the current stock price.

第二重错位：amycretin是市场尚未定价的隐性期权，其三期启动在2026年一季度，但股价还停在管线失败的折价水平

Triple Misalignment 2: Amycretin is an implicit option the market has not yet priced; its Phase 3 launch is in the first quarter of 2026, but the stock price is still stuck at a discount level reflecting pipeline failure.

CagriSema的三期数据令市场失望，但市场的反应是将整个下一代管线一并折价，而忽略了amycretin与CagriSema在分子结构上的本质差异。Amycretin是单一分子的GLP-1与amylin双重激动剂，在二期数据中注射剂型36周减重高达22%，超越Wegovy，在可耐受性与生产效率上均有结构性优势。三期数据若能复现二期表现，将成为诺和诺德最强的反击武器。这个期权，今天的股价并未给出任何溢价。

CagriSema's Phase 3 data disappointed the market, but the market's reaction was to discount the entire next-generation pipeline altogether, ignoring the essential differences in molecular structure between amycretin and CagriSema. Amycretin is a single-molecule GLP-1 and amylin dual agonist; in Phase 2 data, the injectable form showed up to 22% weight loss over 36 weeks, surpassing Wegovy, and possesses structural advantages in tolerability and production efficiency. If Phase 3 data can replicate Phase 2 performance, it will become Novo Nordisk's strongest weapon for a counterattack. Today’s stock price provides no premium for this option.

第三重错位：约11倍市盈率与约4.67%股息收益率构成价值底部，但市场情绪极度悲观，导致估值洼地被忽视

Triple Misalignment 3: A P/E ratio of approximately 11 times and a dividend yield of approximately 4.67% constitute a value floor, but extremely pessimistic market sentiment has caused this valuation trough to be overlooked.

诺和诺德当前市盈率约11倍，远低于医疗保健板块约18倍的平均水平，也低于其自身历史均值。股息收益率约4.67%，在等待基本面修复期间提供持续现金回报。管理层已启动新一轮股票回购计划，与股息并行，显示对当前股价的信心。当市场情绪从极度悲观向中性回归，估值修复本身就是一重独立的回报来源。

Novo Nordisk's current P/E ratio is approximately 11 times, far lower than the healthcare sector average of approximately 18 times, and also lower than its own historical mean. The dividend yield of approximately 4.67% provides continuous cash returns while waiting for fundamental recovery. Management has launched a new round of share buyback programs, running parallel with dividends, showing confidence in the current stock price. When market sentiment returns from extreme pessimism toward neutrality, valuation recovery itself becomes an independent source of return.

关键催化剂时间节点

Key catalyst timelines

2026年上半年：口服Wegovy美国市场月度处方量数据——验证口服剂型能否真正扩大患者群，是最快的基本面修复信号

First half of 2026: Monthly prescription volume data for oral Wegovy in the U.S. market—verifying whether the oral dosage form can truly expand the patient group, which is the fastest signal for fundamental recovery.

2026年全年：amycretin三期临床进展更新——每一次积极的中期数据都将推动市场重新为管线定价

Full year 2026: Clinical progress updates for amycretin Phase 3—every positive interim data point will drive the market to reprice the pipeline.

2026年二季度：Wegovy 7.2mg高剂量版本在更多市场的推进情况——若高剂量减重效果与Zepbound相当，将直接改写竞争格局叙事

Second quarter of 2026: Progress of the Wegovy 7.2mg high-dose version in more markets—if the high-dose weight loss effect is comparable to Zepbound, it will directly rewrite the competitive landscape narrative.

2026年5月6日：下一次季报——管理层对口服Wegovy销售进展的指引是最关键的短期催化剂

May 6, 2026: Next quarterly report—management's guidance on the sales progress of oral Wegovy is the most critical short-term catalyst.

2026年全年：CagriSema重新设计后的临床方案结果——第二次机会，若数据改善将带动市场重估管线价值.

Full year 2026: Clinical protocol results for CagriSema after redesign—a second chance; if data improves, it will drive a market revaluation of the pipeline.

下半部分，我们会给出具体的分批建仓价位、三个阶段的止盈目标，以及哪些信号出现时需要立即离场。

In the second half, we will provide specific staggered entry price levels, three-stage take-profit targets, and signals that would require an immediate exit.